Faron Pharmaceuticals (UK) Today
| FARN Stock | 190.00 2.50 1.33% |
PerformanceModest
| Odds Of DistressBelow Average
|
Faron Pharmaceuticals is selling for under 190.00 as of the 23rd of March 2025; that is 1.33% up since the beginning of the trading day. The stock's lowest day price was 190.0. Faron Pharmaceuticals has about a 43 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 23rd of December 2024 and ending today, the 23rd of March 2025. Click here to learn more.
Moving against Faron Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Faron Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Faron Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Faron Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Health Care, Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors) |
Faron Pharmaceuticals Oy (FARN) is traded on London Exchange in UK and employs 25 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 212.04 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Faron Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Faron Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Faron Pharmaceuticals operates under Biotechnology sector and is part of Health Care industry. The entity has 111.6 M outstanding shares.
Faron Pharmaceuticals generates negative cash flow from operations
Check Faron Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationFaron Pharmaceuticals holds a total of 111.6 Million outstanding shares. Faron Pharmaceuticals Oy retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Faron Ownership Details
Faron Pharmaceuticals Risk Profiles
Although Faron Pharmaceuticals' alpha and beta are two of the key measurements used to evaluate Faron Pharmaceuticals' performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.08 | |||
| Semi Deviation | 2.27 | |||
| Standard Deviation | 3.71 | |||
| Variance | 13.77 |
Faron Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Faron Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Theme Ratings Now
Theme RatingsDetermine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
| All Next | Launch Module |
Faron Pharmaceuticals Corporate Management
Elected by the shareholders, the Faron Pharmaceuticals' board of directors comprises two types of representatives: Faron Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Faron. The board's role is to monitor Faron Pharmaceuticals' management team and ensure that shareholders' interests are well served. Faron Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Faron Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Juhana Heinonen | Chief Officer | Profile | |
| Birge MD | Interim Officer | Profile | |
| Vesa LLM | General Counsel | Profile | |
| MD MSc | Chief Officer | Profile | |
| Jennifer SmithParker | Head Communications | Profile | |
| Maija Hollmen | Chief Officer | Profile |
Additional Tools for Faron Stock Analysis
When running Faron Pharmaceuticals' price analysis, check to measure Faron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Faron Pharmaceuticals is operating at the current time. Most of Faron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Faron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Faron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Faron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.